Our Partners

Through a history of many successful collaborations, Santen has built global alliances with venture businesses, universities, research centers, and other pharmaceutical companies. These partnerships continue to bring us closer to our goal of reducing the loss of social and economic opportunities for people around the world due to eye diseases and problems.

Our Partners
Dec. 2021
Aerie Pharmaceuticals, Inc.

Santen and Aerie announced a global expansion of the exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® and Rocklatan®/ Roclanda® executed in October 2020 by concluding a new agreement to target additional territories, including Europe, China and several other regions.

Aug. 2021
Sydnexis Inc.

Santen SA and Sydnexis Inc. entered into an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia, for Europe, Middle East and Africa (EMEA). SYD-101 is currently undergoing a large multicenter phase III clinical trial in Europe and the US.

May. 2021
Glaukos Corporation

Santen entered into an expanded collaboration in the development and commercialization with Glaukos Corporation for the product development, commercialization, and sales of the Santen owned STN2000100 surgical device (DE-128) in North, Central, and South America, Australia and New Zealand, in addition to the U.S. executed in 2019.

Oct. 2020
Aerie Pharmaceuticals, Inc.

Santen and Aerie Pharmaceuticals, Inc. entered into an exclusive development and commercialization agreement for Rhopressa® (netarsudil ophthalmic solution) and Rocklatan® (netarsudil and latanoprost ophthalmic solution) for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases in Japan, along with rights for several other Asian countries.

Jul. 2020
Osmotica Pharmaceuticals plc

Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, entered into an exclusive license agreement covering the development, registration, and commercialization rights in Japan, China, and other Asian countries as well as EMEA countries to RVL-1201, oxymetazoline hydrochloride ophthalmic solution 0.1%, which is the first and only ophthalmic formulation approved in the United States for the treatment of acquired blepharoptosis or ptosis in adults.

Jun. 2020
Plano Pte. Ltd.

Santen and Plano concluded a strategic alliance to tackle the global burden of myopia.

May. 2020
jCyte, Inc.

Santen and jCyte Inc. concluded an exclusive licensing contract covering the development, registration and commercialization rights in Japan, Asia and Europe to jCell, a first-in-class investigational therapy in currently in clinical development for retinitis pigmentosa.

Feb. 2020
Verily

Santen and Verily, an Alphabet company, established a joint venture to develop and commercialize unique ophthalmic devices focused on applying microelectronics and scalable digital technologies to ophthalmology.

Jan. 2020
International Telecommunication Union

Santen and ITU, the United Nations specialized agency for information and communication technologies, entered into a partnership agreement to support “Be He@lthy, Be Mobile” in ophthalmology, an initiative of ITU and the World Health Organization.

Sep. 2019
Mitsubishi Tanabe Pharma Corporation

Santen and Mitsubishi Tanabe Pharma Corporation concluded a joint sales promotion contract concerning Alesion® Ophthalmic Solution 0.05% (JAN: epinastine hydrochloride), which is an anti-allergenic ophthalmic solution currently manufactured and marketed by Santen, and Alesion® LX, for which Santen has recently obtained approval.

Jun. 2019
Oxford Biomedica (UK) Limited

Santen and Oxford Biomedica entered into an R&D Collaboration and Option & License Agreement to research and develop gene therapy products for the treatment of an inherited retinal disease.

Apr. 2019
Glaukos Corporation

Santen Inc., a subsidiary of Santen Pharmaceutical, and Glaukos entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market.

Sep. 2018
PeptiDream Inc.

Santen and PeptiDream entered into a broad-based multi-target discovery and development agreement, under which PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple ophthalmic disease targets of interest selected by Santen, and to optimize hit peptides into therapeutic peptides products for such indications.

Aug. 2016
InnFocus, Inc.

Santen completed the acquisition of InnFocus, Inc., developer of the InnFocus MicroShunt®, glaucoma implant device.

Mar. 2016
ONO PHARMACEUTICAL CO., LTD.

Santen and ONO entered into an exclusive license agreement whereby Santen will develop and commercialize ONO-9054, an FP/EP3 dual agonist for the treatment for glaucoma and ocular hypertension developed by ONO, on a worldwide basis.

Aug. 2015
AYUMI Pharmaceutical

Santen announced the completion of the transfer of anti-rheumatic pharmaceuticals business to Ayumi Pharmaceutical Corporation.

May. 2014
MERCK

Santen and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (Merck, known as MSD outside of the United States and Canada) signed an agreement for the purchase of ophthalmology products.

Apr. 2014
AKORN

Santen and Oak Pharmaceuticals, Inc., a subsidiary of Akorn, Inc. entered into a license agreement for sales and marketing of ZIOPTAN® in the US market.